Tilff, Belgium

Georges Dive

This inventor holds 2 USPTO granted patents. Top assignees: Societe De Conseils De Recherches Et D'applications Scientifiques, Societe De Conseils De Recherches Et D'applications Scientifiques (s.c.r.a.s.). Active years: 1990.


% Patents Active = 100.0

Average Co-Inventor Count = 4.4

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 1990

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations of Georges Dive

Introduction

Georges Dive is a notable inventor based in Tilff, Belgium. He has made significant contributions to the field of chemistry, particularly in the development of piperazine derivatives. With a total of 2 patents, his work has implications in therapeutic compositions.

Latest Patents

Georges Dive's latest patents include "2-methoxycarbonyl substituted N,N'-di-(trimethoxybenzoyl) piperazines." This invention relates to piperazine derivatives characterized by a specific general formula, wherein Y and Z represent various substituents. The patent also details a preparation process for these compounds and their use as active ingredients in therapeutic compositions. Another significant patent is for "2-carbonyl substituted N,N'-di-(trimethoxybenzoyl)piperazines," which similarly focuses on piperazine derivatives and their preparation processes.

Career Highlights

Throughout his career, Georges Dive has worked with various organizations, including the Société de Conseils de Recherches et d'Applications Scientifiques (SCRAS). His innovative work has contributed to advancements in medicinal chemistry and therapeutic applications.

Collaborations

Georges Dive has collaborated with notable individuals in his field, including Jean-Jacques Godfroid and Francoise Heymans. These collaborations have likely enriched his research and development efforts.

Conclusion

Georges Dive's contributions to the field of chemistry through his patents and collaborations highlight his role as an influential inventor. His work continues to impact therapeutic compositions and piperazine derivatives.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…